Evaluation of Quality of Life in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic
Evaluation of Quality of Life, Physical Activity and Depression in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Çankaya
-
Ankara, Çankaya, Turkey, 06490
- Zeliha ÇELİK
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Having been diagnosed with Type 1 Diabetes Mellitus
- Willing to participate in the study
- Participants whose native language is Turkish
Exclusion Criteria:
- Unwilling to participate in the study
- Having a cognitive disorder
- Not being literate
- Individuals who do not have sufficient knowledge and functional levels to fill out the online form
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with type 1 diabetes mellitus
Patients with Type 1 diabetes mellitus willing to participate in the study
|
Online surveys will be applied to all participants
|
|
Healthy controls
Healthy controls without chronic disease willing to participate in the study
|
Online surveys will be applied to all participants
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical activity level
Time Frame: Five minutes
|
Physical activity level using International Physical Activity Questionnaire - Short Form (IPAQ-SF) will be evaluated.
|
Five minutes
|
|
General Quality of life
Time Frame: Ten minutes
|
Quality of life using Short Form Health Survey (SF-36) will be evaluated.
|
Ten minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depression
Time Frame: Three minutes
|
Depression using Hospital Anxiety and Depression Scale will be evaluated.
|
Three minutes
|
|
Anxiety
Time Frame: Three minutes
|
Anxiety using Hospital Anxiety and Depression Scale will be evaluated.
|
Three minutes
|
|
Self-reported hypoglycemia
Time Frame: Last seven day
|
It will be questioned how many times patients have had hypoglycemic attacks (<4 mmol/L and common symptoms) in the last 7 days.
|
Last seven day
|
|
Loneliness
Time Frame: Three minutes
|
Loneliness using UCLA Loneliness Scale Short Form (ULS-8) will be evaluated.
|
Three minutes
|
|
Hypoglisemia fear
Time Frame: Five minutes
|
Hypoglisemia fear using Hypoglisemia Fear Survey (HFS) will be evaluated.
|
Five minutes
|
|
Dyspnea
Time Frame: Two minutes
|
Dyspnea during daily life activites using Modified Medical Research Dyspnea Scale will be evaluated.
|
Two minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Meral Boşnak Güçlü, Prof, Gazi University
- Study Chair: Zeliha Çelik, MsC, Gazi University
- Principal Investigator: Füsun BALOŞ TÖRÜNER, Prof, Gazi University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Autoimmune Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Endocrine System Diseases
- COVID-19
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
Other Study ID Numbers
Other Study ID Numbers
- 91610558-604.01.02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
NCT04981769Not yet recruiting
-
NCT04885764Recruiting
-
NCT04608305Completed
-
NCT04864925Completed
-
NCT05045846Completed
-
NCT04973735Active, not recruiting
-
NCT04773756Completed
Clinical Trials on Online Survey
-
NCT04855058CompletedFractures, Bone | Medicine, Korean Traditional
-
NCT04410835RecruitingPsychological Distress | Corona Virus Infection | Psychiatric Disorder
-
NCT07178548CompletedLow Back Pain | Guideline Adherence | Physiotherapist | Physiotherapist Students
-
NCT03628235Completed
-
NCT04412278CompletedCOVID | Isolation, Social
-
NCT07483905Not yet recruiting
-
NCT05234034RecruitingPhysical Activity | Chronic Musculoskeletal Disease | Exercise Intensity | Online Survey